優化雙免疫檢查點抑制劑處方中的CTLA-4抗體用法以治療肝癌( I )=Optimization of Anti- Cytotoxic T Lymphocyte Antigen-4 (Anti-Ctla-4) Treatment in Dual Immune Checkpoint Blockade for Hepatocellular Carcinoma( I )

2025-05-052025-05-05https://scholars.lib.ntu.edu.tw/handle/123456789/728817我們的研究結果預期可獲得anti-CTLA-4劑量、次數與用法對於T細胞priming、腫瘤浸潤T細胞活化，以及抗腫瘤療效差異，可為anti-PD-1/PD-L1與anti-CTLA-4合併治療的最佳給藥方式提供新思維，指引臨床上合併治療的使用原則。anti-CTLA-4anti-PD-1雙免疫檢查點阻斷肝癌anti-CTLA-4anti-PD-1dual immune checkpoint blockadehepatocellular carcinoma優化雙免疫檢查點抑制劑處方中的CTLA-4抗體用法以治療肝癌( I )=Optimization of Anti- Cytotoxic T Lymphocyte Antigen-4 (Anti-Ctla-4) Treatment in Dual Immune Checkpoint Blockade for Hepatocellular Carcinoma( I )